In-Silico Study, Synthesis and Pharmacological Screening of Novel Benzopyran-3-Carbonyl Derivatives as Antidiabetic Agents

Abstract

Introduction: In the current work, in-silico docking investigation for 60 benzopyran-3-carbonyl derivatives was conducted since benzopyran derivatives play a vital role in many different research disciplines. Since benzopyran derivatives are important in many different study fields, an in-silico docking analysis for 60 benzopyrancarbonyl derivatives was carried out in the current work. A docking study was carried out to investigate the antidiabetic efficacy of the protein α-amylase (PDB ID: 1OSE) crystal structure. Significant docking scores exhibits anti-diabetic action from D1, D4, D10, D12, D13, D16 and D19. The starting material for the synthesis of novel benzopyran-3-carbonyl derivatives was 3,4-diaminobenzoic acid resulting in a final product like 1-(6-chloro-2-oxo-2H-1-benzopyran-3-carbonyl)-1H-benzotriazole-5-carbohydrazide (D1–D20). At 100 g/ml, the benzopyran-3-carbonyl derivatives exhibited 24.67% (D10) α-amylase inhibitory activity, with an IC50 value of 72.55 g/ml. Benzopyran-3-carbonyl derivatives significantly inhibited α-amylase activity when compared to acarbose. The results show moderate to poor antihyperglycemic action in STZ-induced diabetic rats, with benzopyran-3-carbonyl derivatives showing notably lower blood glucose AUC. The most significant change between the standard and benzopyran-3-carbonyl derivatives was a 24-hour drop in blood glucose of 155 mg/dl.